Favre Touts Experimental Parkinson's Drug, Sparking Hope and Scrutiny

LAS VEGAS, NV – May 14, 2026 – An unsolicited social media post from NFL Hall of Famer Brett Favre has cast a powerful spotlight on an experimental Parkinson's disease treatment, igniting a wave of hope among patients while raising questions within the medical community. Favre, who publicly disclosed his diagnosis in 2024, announced that he has received an investigational therapy from Zhittya Genesis Medicine and has subsequently been able to reduce his conventional medication.

The announcement provides a high-profile testimonial for the Las Vegas-based biopharmaceutical company as it marks the four-year anniversary of its research into intranasal Fibroblast Growth Factor-1 (FGF-1) for Parkinson's disease. The convergence of a beloved sports icon's personal health journey with a company's scientific milestone has created a potent narrative that is now navigating the complex intersection of celebrity, science, and patient advocacy.

A Legend's Public Battle

In a post to his verified X account, Favre detailed his recent experience. "A few months ago I met Dan Montano the CEO of Zhittya, Inc.," he wrote. "They have treated me twice intranasally with the biologic, FGF-1 to enhance blood flow to my brain. I had no side effects and I'm happy to say I've been able to significantly reduce my dopamine medication levels!"

Favre's message highlights a core challenge for the estimated one million Americans living with Parkinson's: the reliance on dopamine replacement therapies like levodopa. While these drugs are the gold standard for managing motor symptoms such as tremors and rigidity, they do not halt the underlying progression of the disease and can come with their own set of long-term side effects. The prospect of reducing this dependency is a compelling one for many patients.

Favre's openness has brought significant attention to the condition. His decision to share his treatment journey adds a personal, results-oriented dimension to the often abstract world of clinical research, resonating deeply with a public hungry for medical advancements.

The Science of FGF-1: Targeting a 'Root Cause'?

For more than two decades, Zhittya Genesis Medicine has been researching FGF-1, a naturally occurring protein in the human body known to stimulate the growth of new blood vessels, a process called angiogenesis. The company's central hypothesis is that many neurodegenerative diseases, including Parkinson's, are exacerbated by compromised blood flow in the brain. Specifically, they theorize that a lack of microvasculature in the substantia nigra—the brain region where dopamine-producing neurons die off—is a key part of the disease pathology.

"For decades, the standard of care in Parkinson's has been confined to symptom management through dopamine replacement," said Dr. Jack Jacobs, Zhittya's President and Chief Science Officer, in a statement. "What we are seeing across our research cohort suggests something fundamentally different — a therapeutic approach that targets the underlying neurovascular pathology, restoring blood flow and giving neurons the environment they need to survive."

This approach aims to shift the treatment paradigm from merely managing symptoms to potentially addressing a root cause. Preclinical studies on monkey and rodent models of Parkinson's have shown promising results, with FGF-1 treatment leading to improved motor function, increased dopamine production, and even regeneration of some dopaminergic neurons. This foundation provides a scientifically plausible basis for the company's human trials.

From Lab to Patient: The Evidence So Far

According to the company, Favre is one of more than 250 individuals with Parkinson's who have participated in its intranasal FGF-1 research protocols. Zhittya has reported observing an average motor skill improvement of 54% in treated patients.

To further validate these observations, the company has collaborated with Washington University School of Medicine in St. Louis on functional magnetic resonance imaging (fMRI). Data from a single patient showed a 21.2% increase in blood flow to the substantia nigra after six months of therapy, which correlated with a 50% improvement in motor skills. While intriguing, this finding is based on a single case and awaits replication in a larger group.

However, the path from these early research studies to a widely available, approved therapy is long and fraught with challenges. A search of clinical trial registries reveals a Phase 1 pilot study for intranasal FGF-1 in the Bahamas, but its status is listed as "Not yet enrolling." The company primarily describes its current work as "Medical Research Studies" and "Compassionate Use Clinical Trials," which operate outside the structure of the large-scale, placebo-controlled trials required for FDA approval in the United States.

Independent medical experts urge caution, emphasizing the preliminary nature of the data. "FGF-1 isn't FDA approved for Parkinson's. It is not a disease modifying therapy at this point in time, a proven neurorestorative intervention," noted one neurologist not affiliated with the company. The expert also pointed out that while human data is very limited, the translation from animal models to human success in neurodegenerative disease has historically been difficult.

The Favre Effect: Hope and Hurdles

Favre's endorsement is a powerful tool for raising awareness, but it also highlights the ethical complexities of promoting an investigational therapy. The visibility can create immense hope, but also potential demand for a treatment that has not yet completed the rigorous scientific validation process. Experts note that some participants in early-stage trials, including those conducted by Zhittya, may be required to cover their own travel and lodging, a financial burden that can accompany the pursuit of cutting-edge but unproven medicine.

Zhittya's ambitions for FGF-1 extend beyond Parkinson's. The company is also investigating its potential for a host of other conditions where compromised blood flow is implicated, including Type 2 Diabetes, Multiple Sclerosis, stroke, and Post-Concussion Syndrome. This positions FGF-1 as a potential platform technology in the burgeoning field of regenerative medicine.

For now, Brett Favre's public declaration has galvanized the Parkinson's community, offering a tangible story of hope. His experience, and that of the other research participants, will be watched closely by patients, physicians, and regulators as Zhittya Genesis Medicine works to turn its promising initial findings into scientifically proven, accessible medicine.